Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 23 ... 1.0 and 2.0 centimeters as measured by transvaginal ultrasound at mid-pregnancy. The primary endpoint of the study is a reduction in the incidence of preterm birth at less than or equal to ...
2009 NOV 23 ... hyperplasia ("BPH"). The efficacy study Z-033 did not achieve its primary endpoint. Results from the safety study Z-041 were positive and exhibited a similar ...
2009 NOV 23 ... dirucotide, the lead drug covered by AutoImmune's license agreement, did not meet the primary endpoint of delaying disease progression during a two-year Phase III trial in patients with ...
2009 NOV 23 ... chemotherapy, and also in patients who only receive surgery as a standard of care. The primary endpoint of the trial is disease-free survival. ASCI is an investigational class of ...
2009 NOV 23 ... strength of the Phase II data in melanoma, we are optimistic that OncoVEX will meet its primary endpoint in the current Phase III study and that its potential will be realized in melanoma and ...
2009 NOV 23 ... doxorubicin for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer, and recurrent chest wall breast cancer. "We achieved key ... and the FDA has agreed to progression free survival as the primary and accelerated endpoint with overall survival being a secondary endpoint. The trial will enroll up to six ...
2009 NOV 25 ... in the study was suspended after randomization of 60% of the planned 195 subjects. The primary efficacy endpoint was the mean change in the International Restless Legs Syndrome Rating ...
2009 NOV 23 ... randomized to desloratadine 5 mg/day (n = 293) or placebo/day (n = 291) for 28 days. Primary endpoint was change from baseline in a.m./p.m. nasal congestion score. included change from ...
2009 NOV 23 ... 15 plus carboplatin given on day 1 of a 21-day cycle (dose-dense regimen; n=317). The primary endpoint was progression-free survival. Analysis was by intention to treat (ITT). This trial is ...
2009 NOV 29 ... Overall survival (OS) may be a reasonable primary endpoint when the median survival postprogession (SSP) is less than 6 months, but it is too high ...
2009 NOV 23 ... positive data from the first Phase 3 trial which showed that fidaxomicin met its primary endpoint of non-inferiority of clinical cure compared to Vancocin=AE. In addition, patients ...
2009 NOV 23 ... to treatment. All patients received vitamin B-12, folic acid, and dexamethasone. The primary endpoint of progression-free survival and the secondary endpoint of overall survival were ...
2009 NOV 23 ... outcome (PRO) measures, with a focus on urgency severity. Results for the primary endpoint, reductions in daily urgency episodes, and other bladder-diary variables have been ...
2009 NOV 23 ... 140 mg/m2 was administered intravenously on days 1 and 15 of a 4-week cycle. The primary endpoint was the response rate. Secondary endpoints were progression-free survival (PFS), overall ...
2009 NOV 23 ... patients demonstrated a statistically significant improvement for both the primary endpoint and key secondary endpoint compared to placebo patients. Rifaximin delivered adequate ...
2009 NOV 16 ... 34 percent in the pioglitazone group, and 43 percent in the vitamin E group met the primary endpoint, which was a predetermined histological improvement and no worsening of fibrosis. ...
2009 NOV 23 ... the control group, respectively, include technical success (97% vs 97%; P = 1.00); primary patency (53% vs 58%; P = .58); freedom from target lesion revascularization (73% vs 69%; ... were successfully recanalized with the Crosser catheter. Regarding the primary safety endpoint, there were no clinical perforations related to the Crosser. Another endpoint was ...
